Depomed Stock Price, News & Analysis (NASDAQ:DEPO)

$8.45 -0.01 (-0.12 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$8.46
Today's Range$8.15 - $8.50
52-Week Range$4.31 - $21.38
Volume1.38 million shs
Average Volume1.66 million shs
Market Capitalization$532.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:DEPO
CUSIP24990810
Phone+1-510-7448000

Debt

Debt-to-Equity Ratio2.90%
Current Ratio0.83%
Quick Ratio0.79%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$455.90 million
Price / Sales1.17
Cash Flow$0.63 per share
Price / Cash13.35
Book Value$4.07 per share
Price / Book2.08

Profitability

Trailing EPS($1.83)
Net Income$-88,720,000.00
Net Margins-27.73%
Return on Equity-51.07%
Return on Assets-10.00%

Miscellaneous

Employees490
Outstanding Shares63,010,000

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) released its earnings results on Tuesday, November, 7th. The specialty pharmaceutical company reported $0.14 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.02. The specialty pharmaceutical company had revenue of $95.40 million for the quarter, compared to the consensus estimate of $99.11 million. Depomed had a negative return on equity of 51.07% and a negative net margin of 27.73%. The company's revenue for the quarter was down 13.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.28 earnings per share. View Depomed's Earnings History.

When will Depomed make its next earnings announcement?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, February, 19th 2018. View Earnings Estimates for Depomed.

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

8 equities research analysts have issued 1-year price objectives for Depomed's shares. Their forecasts range from $5.00 to $24.00. On average, they anticipate Depomed's stock price to reach $11.75 in the next year. View Analyst Ratings for Depomed.

What are Wall Street analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

  • James P. Fogarty CPA, Chairman of the Board (Age 49)
  • Arthur J. Higgins, President, Chief Executive Officer, Director (Age 61)
  • August J. Moretti, Chief Financial Officer, Senior Vice President (Age 66)
  • Santosh J. Vetticaden M.D. Ph.D., Senior Vice President, Chief Medical and Scientific Officer
  • Matthew M. Gosling, Senior Vice President, General Counsel (Age 46)
  • Sharon D. Larkin, Senior Vice President - Human Resources and Administration. (Age 53)
  • Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality (Age 49)
  • Karen A. Dawes, Independent Director (Age 64)
  • Louis J. Lavigne Jr., Independent Director (Age 69)
  • William T. McKee CPA, Independent Director (Age 55)

Who owns Depomed stock?

Depomed's stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (3.68%), State of Wisconsin Investment Board (1.52%), Deltec Asset Management LLC (1.46%), OxFORD Asset Management LLP (0.75%), Schwab Charles Investment Management Inc. (0.59%) and Nordea Investment Management AB (0.57%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Who sold Depomed stock? Who is selling Depomed stock?

Depomed's stock was sold by a variety of institutional investors in the last quarter, including Litespeed Management L.L.C., Gabelli Funds LLC, Deltec Asset Management LLC, Hussman Strategic Advisors Inc., Candriam Luxembourg S.C.A., Comerica Bank and Gamco Investors INC. ET AL. View Insider Buying and Selling for Depomed.

Who bought Depomed stock? Who is buying Depomed stock?

Depomed's stock was acquired by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Nordea Investment Management AB, Engineers Gate Manager LP, GSA Capital Partners LLP, OxFORD Asset Management LLP, Systematic Financial Management LP, Cubist Systematic Strategies LLC and Stevens Capital Management LP. View Insider Buying and Selling for Depomed.

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of Depomed stock can currently be purchased for approximately $8.45.

How big of a company is Depomed?

Depomed has a market capitalization of $532.46 million and generates $455.90 million in revenue each year. The specialty pharmaceutical company earns $-88,720,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Depomed employs 490 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 Gateway Blvd Ste 300, NEWARK, CA 94560-1188, United States. The specialty pharmaceutical company can be reached via phone at +1-510-7448000 or via email at [email protected]


MarketBeat Community Rating for Depomed (DEPO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Depomed (NASDAQ:DEPO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.442.332.302.60
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.89$11.78$14.10$18.50
Price Target Upside: 54.73% upside83.45% upside130.39% upside88.01% upside

Depomed (NASDAQ:DEPO) Consensus Price Target History

Price Target History for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2017Royal Bank of CanadaSet Price TargetHold$9.00MediumView Rating Details
12/7/2017Piper Jaffray CompaniesReiterated RatingHold$9.00HighView Rating Details
12/5/2017MizuhoUpgradeNeutral -> Buy$9.00HighView Rating Details
11/9/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
8/8/2017Janney Montgomery ScottDowngradeBuy -> Neutral$18.00 -> $8.00HighView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Depomed (NASDAQ:DEPO) Earnings History and Estimates Chart

Earnings by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018$0.12N/AView Earnings Details
11/7/2017Q3 2017$0.12$0.14$99.11 million$95.40 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09($0.43)$100.40 million$100.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Depomed (NASDAQ:DEPO) Earnings Estimates

2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.20)($0.23)
Q2 20172($0.32)($0.04)($0.18)
Q3 20172($0.05)$0.04($0.01)
Q4 20172$0.05$0.38$0.22
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Depomed (NASDAQ:DEPO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Depomed (NASDAQ DEPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 90.99%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Depomed (NASDAQ DEPO) News Headlines

Source:
DateHeadline
Depomed Inc (undefined:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?Depomed Inc (undefined:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - December 13 at 5:31 PM
Depomed (DEPO) Lifted to Hold at BidaskClubDepomed (DEPO) Lifted to Hold at BidaskClub
www.americanbankingnews.com - December 10 at 4:32 PM
 Analysts Anticipate Depomed, Inc. (DEPO) Will Post Quarterly Sales of $92.77 Million Analysts Anticipate Depomed, Inc. (DEPO) Will Post Quarterly Sales of $92.77 Million
www.americanbankingnews.com - December 9 at 8:26 AM
Depomed (DEPO) PT Set at $9.00 by Royal Bank Of CanadaDepomed (DEPO) PT Set at $9.00 by Royal Bank Of Canada
www.americanbankingnews.com - December 8 at 6:06 PM
Investors Purchase Large Volume of Call Options on Depomed (DEPO)Investors Purchase Large Volume of Call Options on Depomed (DEPO)
www.americanbankingnews.com - December 8 at 1:32 AM
ETFs with exposure to Depomed, Inc. : December 7, 2017ETFs with exposure to Depomed, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:47 PM
$0.10 Earnings Per Share Expected for Depomed, Inc. (DEPO) This Quarter$0.10 Earnings Per Share Expected for Depomed, Inc. (DEPO) This Quarter
www.americanbankingnews.com - December 7 at 3:39 PM
Depomed (DEPO) Receives Hold Rating from Piper Jaffray CompaniesDepomed (DEPO) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - December 7 at 7:56 AM
Depomed Executes an Exit Strategy for Its Opioid DrugDepomed Executes an Exit Strategy for Its Opioid Drug
www.fool.com - December 6 at 1:34 PM
Pre-Open Movers 12/05: (RVNC) (COLL) (DEPO) Higher; (ASNA) (DPW) (HRTX) Lower (more...)Pre-Open Movers 12/05: (RVNC) (COLL) (DEPO) Higher; (ASNA) (DPW) (HRTX) Lower (more...)
www.streetinsider.com - December 6 at 9:38 AM
Depomed (DEPO) Upgraded to "Sell" at ValuEngineDepomed (DEPO) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - December 5 at 10:50 PM
Depomed (DEPO) Upgraded to Buy at MizuhoDepomed (DEPO) Upgraded to Buy at Mizuho
www.americanbankingnews.com - December 5 at 6:34 PM
Head to Head Survey: Par Pharmaceutical Companies (PRX) and Depomed (DEPO)Head to Head Survey: Par Pharmaceutical Companies (PRX) and Depomed (DEPO)
www.americanbankingnews.com - December 5 at 12:22 PM
Benzingas Top Upgrades, Downgrades For December 5, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For December 5, 2017 - Benzinga
www.benzinga.com - December 5 at 10:10 AM
Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy - StreetInsider.comMizuho Securities Upgrades DepoMed Inc (DEPO) to Buy - StreetInsider.com
www.streetinsider.com - December 5 at 10:10 AM
Depomed, Inc. :DEPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017Depomed, Inc. :DEPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 10:10 AM
New Partnership for the Commercialization of Nucynta® in the U.S. TerritoryNew Partnership for the Commercialization of Nucynta® in the U.S. Territory
www.prnewswire.com - December 5 at 3:24 AM
BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium PharmaceuticalBRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
www.reuters.com - December 4 at 5:20 PM
Lawsuit for Investors Who Purchased Shares of Depomed Inc. (NASDAQ: DEPO) Announced by Shareholders FoundationLawsuit for Investors Who Purchased Shares of Depomed Inc. (NASDAQ: DEPO) Announced by Shareholders Foundation
finance.yahoo.com - November 28 at 5:20 PM
Depomed, Inc. (DEPO) Receives Consensus Recommendation of "Hold" from AnalystsDepomed, Inc. (DEPO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 26 at 8:06 PM
Depomed to Participate at the Annual Piper Jaffray Healthcare ConferenceDepomed to Participate at the Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 21 at 6:06 PM
 Brokerages Anticipate Depomed, Inc. (DEPO) Will Announce Quarterly Sales of $92.77 Million Brokerages Anticipate Depomed, Inc. (DEPO) Will Announce Quarterly Sales of $92.77 Million
www.americanbankingnews.com - November 21 at 6:24 AM
UBS AG Raises Depomed, Inc. (DEPO) Price Target to $7.00UBS AG Raises Depomed, Inc. (DEPO) Price Target to $7.00
www.americanbankingnews.com - November 12 at 9:48 AM
Depomed, Inc. (DEPO) Receives Hold Rating from Piper Jaffray CompaniesDepomed, Inc. (DEPO) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - November 11 at 9:42 AM
Depomed Inc. 2017 Q3 - Results - Earnings Call SlidesDepomed Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 10 at 5:49 PM
Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : November 10, 2017Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : November 10, 2017
finance.yahoo.com - November 10 at 5:49 PM
Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : November 9, 2017Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : November 9, 2017
finance.yahoo.com - November 10 at 9:30 AM
ETFs with exposure to Depomed, Inc. : November 9, 2017ETFs with exposure to Depomed, Inc. : November 9, 2017
finance.yahoo.com - November 10 at 9:30 AM
Depomed, Inc. (DEPO) Upgraded at Morgan StanleyDepomed, Inc. (DEPO) Upgraded at Morgan Stanley
www.americanbankingnews.com - November 9 at 11:54 AM
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions - GlobeNewswire (press release)Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions - GlobeNewswire (press release)
globenewswire.com - November 9 at 12:44 AM
Depomeds (DEPO) CEO Arthur Higgins on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaDepomed's (DEPO) CEO Arthur Higgins on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 12:44 AM
Earnings Reaction History: Depomed, Inc., 87.5% Follow-Through Indicator, 10.4% Sensitive - NasdaqEarnings Reaction History: Depomed, Inc., 87.5% Follow-Through Indicator, 10.4% Sensitive - Nasdaq
www.nasdaq.com - November 9 at 12:44 AM
Edited Transcript of DEPO earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of DEPO earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 12:44 AM
Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%
finance.yahoo.com - November 9 at 12:44 AM
Depomed (DEPO) to Acquire U.S. Rights to Cosyntropin, Divest Lazanda in Pact with SlanDepomed (DEPO) to Acquire U.S. Rights to Cosyntropin, Divest Lazanda in Pact with Slan
www.streetinsider.com - November 8 at 1:42 AM
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset TransactionsDepomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions
finance.yahoo.com - November 8 at 1:42 AM
Depomed Announces Third Quarter 2017 Financial ResultsDepomed Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 1:42 AM
Depomed reports 3Q lossDepomed reports 3Q loss
finance.yahoo.com - November 8 at 1:42 AM
Depomed, Inc. (DEPO) Releases Quarterly  Earnings Results, Beats Estimates By $0.02 EPSDepomed, Inc. (DEPO) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 7 at 5:27 PM
Financial Survey: Par Pharmaceutical Companies (PRX) and Depomed (DEPO)Financial Survey: Par Pharmaceutical Companies (PRX) and Depomed (DEPO)
www.americanbankingnews.com - November 7 at 2:06 PM
Depomed, Inc. (DEPO) Given Average Rating of "Hold" by BrokeragesDepomed, Inc. (DEPO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 1 at 11:36 PM
Depomed, Inc. (DEPO) Expected to Announce Quarterly Sales of $98.92 MillionDepomed, Inc. (DEPO) Expected to Announce Quarterly Sales of $98.92 Million
www.americanbankingnews.com - November 1 at 5:52 PM
Depomed to Report Third Quarter 2017 Financial Results on Tuesday, November 7, 2017 - GlobeNewswire (press release)Depomed to Report Third Quarter 2017 Financial Results on Tuesday, November 7, 2017 - GlobeNewswire (press release)
globenewswire.com - November 1 at 12:02 AM
Depomed to Report Third Quarter 2017 Financial Results on Tuesday, November 7, 2017Depomed to Report Third Quarter 2017 Financial Results on Tuesday, November 7, 2017
finance.yahoo.com - October 31 at 7:00 PM
PDL BioPharma And Depomed Reach Settlement Agreement With Valeant - NasdaqPDL BioPharma And Depomed Reach Settlement Agreement With Valeant - Nasdaq
www.nasdaq.com - October 30 at 11:35 PM
Depomed, Inc. (DEPO) Scheduled to Post Quarterly Earnings on MondayDepomed, Inc. (DEPO) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:14 AM
Royal Bank Of Canada Reiterates $8.00 Price Target for Depomed, Inc. (DEPO)Royal Bank Of Canada Reiterates $8.00 Price Target for Depomed, Inc. (DEPO)
www.americanbankingnews.com - October 28 at 11:36 AM
Depomed, Inc. (DEPO) Receives Hold Rating from Royal Bank Of CanadaDepomed, Inc. (DEPO) Receives Hold Rating from Royal Bank Of Canada
www.americanbankingnews.com - October 21 at 8:15 AM
Depomed (DEPO) Names Santosh J. Vetticaden as SVP and Chief Medical and Scientific OfficerDepomed (DEPO) Names Santosh J. Vetticaden as SVP and Chief Medical and Scientific Officer
www.streetinsider.com - October 19 at 6:27 PM
Robbins Arroyo LLP: Depomed, Inc. (DEPO) Misled Shareholders ... - Business Wire (press release)Robbins Arroyo LLP: Depomed, Inc. (DEPO) Misled Shareholders ... - Business Wire (press release)
www.businesswire.com - October 19 at 12:15 AM

SEC Filings

Depomed (NASDAQ:DEPO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Depomed (NASDAQ:DEPO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Depomed (NASDAQ DEPO) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.